


**Amendments to the Claims**

1. (previously presented) A benzisothiazole-3(2H)-one compound of formula (I)



(I)

wherein;

R<sub>1</sub> is the group (C<sub>4</sub>-C<sub>12</sub>)haloalkyl, -CF<sub>3</sub>, (C<sub>1</sub>-C<sub>8</sub>)alkylcycloalkyl, or (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl,

;

R<sub>2</sub> is hydrogen;

R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub>, are each independently selected from hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>4</sub>)alkenyl, -O-(C<sub>1</sub>-C<sub>3</sub> alkyl), COOH, C(O)(C<sub>1</sub>-C<sub>3</sub> alkyl), C(O)O(C<sub>1</sub>-C<sub>3</sub> alkyl), -CF<sub>3</sub>, and halo; or a pharmaceutically acceptable salt thereof.

2. (canceled)

3. (previously presented) A compound according to Claim 1 wherein R<sub>1</sub> is (C<sub>3</sub>-C<sub>4</sub>)alkylcycloalkyl, or -CF<sub>3</sub>.

4. (canceled)

5. (canceled)

6. (previously presented) The compound of Claim 1 wherein R<sub>5</sub> is the group represented by chloro, bromo or CF<sub>3</sub>.

7. (previously presented) A compound selected from the group consisting of:

3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid allylamide;  
3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid cyclohexylamide;  
3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid (4-cyclohexyl-butyl)-amide; and  
6-Chloro-3-oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid cyclohexylamide.

8. (canceled)


9. (previously presented) A pharmaceutical formulation comprising a benzisothiazole-3(2*H*)-one compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

10-15. (canceled)

16. (previously presented) The method of claim 18 wherein the benzisothiazole-3(2*H*)-one compound is formulated with a pharmaceutically acceptable carrier or diluent.

17. (canceled)

18. (previously presented) A method of treating hypercholesterolemia, hyperlipidemia, or atherosclerosis in a mammal in need thereof comprising administering a therapeutically effective amount of benzisothiazole-3(2*H*)-one compound of formula I, wherein R<sub>1</sub>-R<sub>6</sub> are as defined in claim 1



I

or a pharmaceutical acceptable salt thereof.